Literature DB >> 18311803

Matrix metalloproteinase 9 activity leads to elastin breakdown in an animal model of Kawasaki disease.

Andrew C Lau1, Trang T Duong, Shinya Ito, Rae S M Yeung.   

Abstract

OBJECTIVE: Kawasaki disease (KD) is a multisystem vasculitis leading to damage in the coronary circulation and aneurysm formation. Because cardiac tissue from affected children is not available, investigation of the mechanisms responsible for coronary artery damage in KD requires use of a disease model. The present study was undertaken to examine, in an experimental model, the role of matrix metalloproteinase 9 (MMP-9) on coronary artery inflammation and vascular damage.
METHODS: C57BL/6 mice were injected with Lactobacillus casei cell wall extract to induce coronary arteritis. Hearts were isolated and assayed for MMP-9 protein expression and enzymatic activity by immunoblotting or confocal microscopy and zymography, respectively. MMP-9-deficient mice were used to examine the necessity of MMP-9 for disease development.
RESULTS: Localized inflammation at the coronary artery led to elastin breakdown and aneurysm formation. This occurred in the absence of smooth muscle cell apoptosis. Following disease induction, there was an increase in the amount and enzymatic activity of MMP-9, an elastolytic protease. MMP-9 was up-regulated by tumor necrosis factor alpha (TNFalpha) and produced primarily by vascular smooth muscle cells. In MMP-9-deficient animals, vascular inflammation continued to develop, but the incidence of elastin breakdown was significantly reduced. Elastin breakdown in the coronary artery was virtually eliminated by ablation of MMP-9.
CONCLUSION: These findings show that TNFalpha up-regulates expression of MMP-9, an important proteinase responsible for extracellular matrix breakdown, leading to coronary artery damage in this model of KD. These results have important implications regarding treatments for improving coronary outcome in affected children.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18311803     DOI: 10.1002/art.23225

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  32 in total

1.  Study design and rationale to assess Doxycycline Efficacy in preventing coronary Artery Lesions in children with Kawasaki disease (DEAL trial) - A phase II clinical trial.

Authors:  Andras Bratincsak; Blair N Limm-Chan; Vivek R Nerurkar; Lauren L Ching; Venu D Reddy; Eunjung Lim; Ralph V Shohet; Marian E Melish
Journal:  Contemp Clin Trials       Date:  2017-12-05       Impact factor: 2.226

2.  Early gene expression changes induced by the bacterial superantigen staphylococcal enterotoxin B and its modulation by a proteasome inhibitor.

Authors:  Govindarajan Rajagopalan; Ashenafi Y Tilahun; Yan W Asmann; Chella S David
Journal:  Physiol Genomics       Date:  2009-03-31       Impact factor: 3.107

3.  Ascending Aorta Elastography After Kawasaki Disease Compared to Systemic Hypertension.

Authors:  Ian Nandlall; Roch L Maurice; Anne Fournier; Aïcha Merouani; Nagib Dahdah
Journal:  Pediatr Cardiol       Date:  2015-04-29       Impact factor: 1.655

4.  The role of atorvastatin in regulating the immune response leading to vascular damage in a model of Kawasaki disease.

Authors:  S Blankier; B W McCrindle; S Ito; R S M Yeung
Journal:  Clin Exp Immunol       Date:  2011-03-01       Impact factor: 4.330

Review 5.  A cytokine axis regulates elastin formation and degradation.

Authors:  Erin P Sproul; W Scott Argraves
Journal:  Matrix Biol       Date:  2012-11-13       Impact factor: 11.583

6.  Inhibition of transforming growth factor β worsens elastin degradation in a murine model of Kawasaki disease.

Authors:  Cristina M Alvira; Christophe Guignabert; Yu-Mee Kim; Chihhsin Chen; Lingli Wang; Trang T Duong; Rae S M Yeung; Dean Y Li; Marlene Rabinovitch
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

Review 7.  Comparative effectiveness of intravenous immunoglobulin from different manufacturing processes on Kawasaki disease.

Authors:  Ming-Chih Lin
Journal:  World J Pediatr       Date:  2014-05-07       Impact factor: 2.764

8.  Inhibition of matrix metalloproteinase-9 activity improves coronary outcome in an animal model of Kawasaki disease.

Authors:  A C Lau; T T Duong; S Ito; G J Wilson; R S M Yeung
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

9.  Involvement of innate and adaptive immunity in a murine model of coronary arteritis mimicking Kawasaki disease.

Authors:  Danica J Schulte; Atilla Yilmaz; Kenichi Shimada; Michael C Fishbein; Emily L Lowe; Shuang Chen; Michelle Wong; Terence M Doherty; Thomas Lehman; Timothy R Crother; Rosalinda Sorrentino; Moshe Arditi
Journal:  J Immunol       Date:  2009-09-28       Impact factor: 5.422

10.  Advances in biomimetic regeneration of elastic matrix structures.

Authors:  Balakrishnan Sivaraman; Chris A Bashur; Anand Ramamurthi
Journal:  Drug Deliv Transl Res       Date:  2012-10       Impact factor: 4.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.